A synergy control motif within the attenuator domain of CCAAT/enhancer-binding protein alpha inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3 - PubMed (original) (raw)
. 2003 Mar 14;278(11):9134-41.
doi: 10.1074/jbc.M210440200. Epub 2003 Jan 2.
Affiliations
- PMID: 12511558
- DOI: 10.1074/jbc.M210440200
Free article
A synergy control motif within the attenuator domain of CCAAT/enhancer-binding protein alpha inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3
Lalitha Subramanian et al. J Biol Chem. 2003.
Free article
Abstract
One of the most common forms of functional interaction among transcription factors is the more than additive effect at promoters harboring multiple copies of a response element. The mechanisms that enable or control synergy at such compound response elements are poorly understood. We recently defined a common motif within the negative regulatory regions of multiple factors that operates by regulating their transcriptional synergy. We have identified such a synergy control (SC) motif embedded within the "attenuator domain" of CCAAT/enhancer-binding protein alpha (C/EBPalpha), a key regulator of energy homeostasis and cellular differentiation. A Lys(159) --> Arg substitution within the SC motif does not alter C/EBPalpha activity from a single site but leads to enhanced transactivation from synthetic or natural compound response elements. The sequence of SC motifs overlaps with the recently defined consensus SUMO modification site, and we find that the SC motif is the major site of both SUMO-1 and SUMO-3 modification in C/EBPalpha. Furthermore, the disruption of SC motif function is accompanied by loss of SUMO but not ubiquitin modification. C/EBPalpha interacts directly with the E2 SUMO-conjugating enzyme Ubc9 and can be SUMOylated in vitro using purified recombinant components. Notably, we find that PIASy has E3-like activity and enhances both SUMO-1 and SUMO-3 modification of C/EBPalpha in vivo and in vitro. Our results indicate that SUMO modification of SC motifs provides a means to rapidly control higher order interactions among transcription factors and suggests that SUMOylation may be a general mechanism to limit transcriptional synergy.
Similar articles
- Repression and coactivation of CCAAT/enhancer-binding protein epsilon by sumoylation and protein inhibitor of activated STATx proteins.
Kim J, Sharma S, Li Y, Cobos E, Palvimo JJ, Williams SC. Kim J, et al. J Biol Chem. 2005 Apr 1;280(13):12246-54. doi: 10.1074/jbc.M413771200. Epub 2005 Jan 20. J Biol Chem. 2005. PMID: 15661739 - Small ubiquitin-like modifier 1 (SUMO-1) modification of the synergy control motif of Ad4 binding protein/steroidogenic factor 1 (Ad4BP/SF-1) regulates synergistic transcription between Ad4BP/SF-1 and Sox9.
Komatsu T, Mizusaki H, Mukai T, Ogawa H, Baba D, Shirakawa M, Hatakeyama S, Nakayama KI, Yamamoto H, Kikuchi A, Morohashi K. Komatsu T, et al. Mol Endocrinol. 2004 Oct;18(10):2451-62. doi: 10.1210/me.2004-0173. Epub 2004 Jun 10. Mol Endocrinol. 2004. PMID: 15192080 - Identification of a new small ubiquitin-like modifier (SUMO)-interacting motif in the E3 ligase PIASy.
Kaur K, Park H, Pandey N, Azuma Y, De Guzman RN. Kaur K, et al. J Biol Chem. 2017 Jun 16;292(24):10230-10238. doi: 10.1074/jbc.M117.789982. Epub 2017 Apr 28. J Biol Chem. 2017. PMID: 28455449 Free PMC article. - SUMO: getting it on.
Anckar J, Sistonen L. Anckar J, et al. Biochem Soc Trans. 2007 Dec;35(Pt 6):1409-13. doi: 10.1042/BST0351409. Biochem Soc Trans. 2007. PMID: 18031233 Review. - Proteomics strategies to identify SUMO targets and acceptor sites: a survey of RNA-binding proteins SUMOylation.
Filosa G, Barabino SM, Bachi A. Filosa G, et al. Neuromolecular Med. 2013 Dec;15(4):661-76. doi: 10.1007/s12017-013-8256-8. Epub 2013 Aug 25. Neuromolecular Med. 2013. PMID: 23979992 Review.
Cited by
- Sumoylation of transcription factor ETV1 modulates its oncogenic potential in prostate cancer.
Oh S, Shin S, Janknecht R. Oh S, et al. Int J Clin Exp Pathol. 2021 Jul 15;14(7):795-810. eCollection 2021. Int J Clin Exp Pathol. 2021. PMID: 34367411 Free PMC article. - C/EBPß Isoform Specific Gene Regulation: It's a Lot more Complicated than you Think!
Spike AJ, Rosen JM. Spike AJ, et al. J Mammary Gland Biol Neoplasia. 2020 Mar;25(1):1-12. doi: 10.1007/s10911-020-09444-5. Epub 2020 Feb 20. J Mammary Gland Biol Neoplasia. 2020. PMID: 32078094 Free PMC article. Review. - MORC2 regulates C/EBPα-mediated cell differentiation via sumoylation.
Liu J, Zhang Q, Ruan B, Chen W, Zheng J, Xu B, Jiang P, Miao Z, Li F, Guo JY, Cao L, Wang G. Liu J, et al. Cell Death Differ. 2019 Oct;26(10):1905-1917. doi: 10.1038/s41418-018-0259-4. Epub 2019 Jan 15. Cell Death Differ. 2019. PMID: 30644437 Free PMC article. - Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.
Setten RL, Lightfoot HL, Habib NA, Rossi JJ. Setten RL, et al. Curr Pharm Biotechnol. 2018;19(8):611-621. doi: 10.2174/1389201019666180611093428. Curr Pharm Biotechnol. 2018. PMID: 29886828 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
- R01 DK061656/DK/NIDDK NIH HHS/United States
- R01 DK061656-02/DK/NIDDK NIH HHS/United States
- GM 07863/GM/NIGMS NIH HHS/United States
- R01 DK061656-03/DK/NIDDK NIH HHS/United States
- DK61656-01/DK/NIDDK NIH HHS/United States
- R01 DK061656-01/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous